Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Basic): 2010-2025

Historic EPS (Basic) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to -$0.18.

  • Arrowhead Pharmaceuticals' EPS (Basic) rose 86.86% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.05, marking a year-over-year increase of 99.00%. This contributed to the annual value of -$0.01 for FY2025, which is 99.80% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported EPS (Basic) of -$0.18 as of Q3 2025, which was up 85.71% from -$1.26 recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EPS (Basic) peaked at $2.78 during Q1 2025, and registered a low of -$1.39 during Q4 2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EPS (Basic) value was -$1.02 (recorded in 2024), while the average stood at -$0.60.
  • In the last 5 years, Arrowhead Pharmaceuticals' EPS (Basic) plummeted by 321.74% in 2024 and then surged by 372.55% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.60 in 2021, then skyrocketed by 35.00% to -$0.39 in 2022, then plummeted by 217.95% to -$1.24 in 2023, then fell by 12.10% to -$1.39 in 2024, then skyrocketed by 86.86% to -$0.18 in 2025.
  • Its last three reported values are -$0.18 in Q3 2025, -$1.26 for Q2 2025, and $2.78 during Q1 2025.